Thermo Fisher Scientific (TMO) Q2 FY26 earnings call

Thermo Fisher Scientific delivered an outstanding Q2 FY26, surpassing expectations with robust organic revenue growth and adjusted EPS. Customer activity strengthened across all end markets, particularly in Pharma and Biotech, leading to a raised full-year outlook despite minor headwinds from FX and a planned divestiture. The company continues to leverage high-impact innovation and strategic M&A to drive share gains and create value for stakeholders.